What types of diseases is Tepotinib suitable for?

Tepotinib is a targeted therapy drug mainly used to treat non-small cell lung cancer (NSCLC) caused by MET gene mutations. MET gene mutation is a common driver mutation in non-small cell lung cancer, especially in patients without EGFR mutations and ALK rearrangements. MET mutations may be a key factor in tumor development. Tepotinib, as a MET inhibitor, blocks the proliferation and metastasis of tumor cells by targeting the MET signaling pathway and plays an effective therapeutic role.

The primary indication for Tepotinib is the treatment of locally advanced or metastatic non-small cell lung cancer with METexon14 skipping mutations (METex14) or MET gene amplification. METex14Mutation is a relatively rare but clinically significant mutation in patients with non-small cell lung cancer, accounting for approximately 3%-4% of all patients with non-small cell lung cancer. This mutation can lead to overactivation of the MET receptor and promote the growth and spread of cancer cells. Therefore, MET inhibitors can effectively control the progression of such tumors.

In addition to non-small cell lung cancer, tepotinib also has research potential in a number of other cancers associated with MET mutations, including gastric cancer, liver cancer and other solid tumors. While clinical applications for these indications are still in the investigational stage, preliminary data suggest that tepotinib may have some promise in treating some gastrointestinal or other cancers that are positive for MET mutations. Therefore, the application of tepotinib is not limited to lung cancer, and its therapeutic effect in other cancers also deserves further exploration.

In general, tepotinib, as a targeted drug, has shown significant efficacy in the treatment of MET non-small cell lung cancer positive for gene mutations. It provides a new treatment option for patients who have failed traditional chemotherapy or immunotherapy. With the deepening of clinical research, the indications of tepotinib may be further expanded, bringing hope to more patients.

Reference materials:https://www.tepotinib.com/